Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Basic toxicokinetics

Currently viewing:

Administrative data

Endpoint:
basic toxicokinetics in vivo
Type of information:
migrated information: read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
weight of evidence
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Study well documented, meets generally accepted scientific principles, acceptable for assessment

Data source

Reference
Reference Type:
publication
Title:
Pharmacokinetics and distribution of [35S]methylsulfonylmethane following oral administration to rats
Author:
Magnuson BA, Appleton J and Ames GB
Year:
2007
Bibliographic source:
J Agric Food Chem., 55(3):1033-8

Materials and methods

Objective of study:
distribution
excretion
toxicokinetics
Principles of method if other than guideline:
Investigation of the pharmacokinetics, distribution, and excretion of [35S]MSM in rats

Test material

Constituent 1
Chemical structure
Reference substance name:
Dimethyl sulphone
EC Number:
200-665-9
EC Name:
Dimethyl sulphone
Cas Number:
67-71-0
Molecular formula:
C2H6O2S
IUPAC Name:
dimethyl sulfone
Constituent 2
Reference substance name:
Methylsulfonylmethane
IUPAC Name:
Methylsulfonylmethane
Details on test material:
The Methylsulfonylmethane (MSM) used in this study was OptiMSM distilled microprill provided by Cardinal Nutrition, Inc. (Vancouver, WA). Labeled [35S]MSM was prepared by Perkin-Elmer Life Sciences (Boston, MA) as an aqueous solution (5 mCi/mL, 500 mCi/mmol).
Radiolabelling:
yes

Test animals

Species:
rat
Strain:
Sprague-Dawley
Sex:
male
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Taconic Farms (Germantown, NY)
- Age at reception: 7-8 weeks old
- Fasting period before study: overnight and for approximately 4 h postdose
- Housing:
- Diet: Harlan Teklad Certified Rodent Diet 8728C, ad libitum
- Water: ad libitum
- Acclimation period: >1 week

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
water
Duration and frequency of treatment / exposure:
Single
Doses / concentrations
Remarks:
Doses / Concentrations:
500 mg/kg and 50 µCi/rat
Details on dosing and sampling:
Five rats were designated group 1 (blood group), and three rats were designated group 2 (urine and feces group). Samples of blood were collected at 0, 15, and 30 min and 1, 2, 4, 8, 12, 24, and 48 h from group 1. Tissues were collected from group 1 and 2 animals after 48 and 120 h, respectively. Urine and feces were collected during the following time intervals: -24 to 0 (prestudy initiation), 0-24, 24-48, 48-72, 72-96, and 96-120 h after dosing.

PHARMACOKINETIC STUDY (Absorption, distribution, excretion)
- Tissues and body fluids sampled: urine, feces, blood, liver, heart, kidneys, spleen, brain, testes, eyes, scapular skin (shaved), and knee joints (bone and cartilage)s, cage washes
- Time and frequency of sampling: see Table 1

METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled: as above
- Time and frequency of sampling: see Table 1
- From how many animals: see Table 1
- Method type(s) for identification: Liquid scintillation counting
- Limits of detection and quantification: no data
TREATMENT FOR CLEAVAGE OF CONJUGATES (if applicable):
Statistics:
Mean and standard deviation calculations were performed using Excel Office XP (Microsoft, Redmond, WA). Pharmacokinetic analysis of the total
35S blood concentration-time data was calculated by noncompartmental analyses using WinNonlin, version 4.1. (Pharsight Corp., Mountain View, CA).

Results and discussion

Main ADME resultsopen allclose all
Type:
excretion
Results:
Urine (0-120h): 85.8 ± 4.8 % of the dose
Type:
excretion
Results:
Feces (0-120h): 3.0 ± 3.0 %
Type:
excretion
Results:
Total (0-120h): 88.9 ± 5.1 %

Toxicokinetic / pharmacokinetic studies

Details on distribution in tissues:
Blood Concentrations of MSM.
Oral administration of [35S]-MSM to rats resulted in the rapid appearance of substantial blood concentrations of 35S at the first time point of 15 min postdose and quantifiable concentrations at all time points up to 48 h (Figure 1). Radiolabel concentrations remained close to peak levels for 8 h following dose administration (mean blood levels were >80% of the maximal concentration level from 0.5 to 8 h postdose). The peak mean blood concentration of 618 µg equiv/mL was achieved at 2 h following MSM administration. Significant blood concentrations of radioactivity (>70 times the quantifiable level of 0.816 µg equiv/mL) persisted through the 48 h time point. Examination of the blood
concentrations versus time analysis from individual rats revealed that the blood concentration profile was very consistent from rat to rat (data not shown).

Distribution of Radioactivity.
Total radioactivity appeared to be widely distributed throughout the body, and measurable levels of total 35S were found in all tissues analyzed at 48 h postdose (Table 3).
The highest levels of radiolabel were found in kidney, testes, and eye. These values were comparable ((15%) to the blood concentration (63.7 µg equiv/g) found at the 48 h time point. Radioactivity levels in the skin (51.8 µg equiv/g) and bone (35.2 µg equiv/g) were lower than the (15% range. No quantifiable levels of radioactivity (values greater than twice ranging from 0.76 to 2.43 µg equiv/g depending on the tissue) were found in any of the tissues analyzed at the 120 h time point, suggesting that all radioactivity was eliminated by 120 h.
Details on excretion:
Excretion in Urine and Feces.
Following a single admin- istration of [35S]MSM, the majority of the radioactivity (85.8%) was excreted in the urine (Table 4). Only a relatively minor amount of the radioactive dose (3.03%) was excreted in the feces. The majority of the radioactivity (58.7%) was excreted within the first 24 h, with 79.0% excreted by 48 h on the basis of radioactivity in urine and feces. Less than 1% of the radioactivity was found in the cage wash (Table 4).
Toxicokinetic parametersopen allclose all
Toxicokinetic parameters:
Cmax: 622 ± 37 µg equiv/mL
Toxicokinetic parameters:
Tmax: 2.1 ± 1.2 h
Toxicokinetic parameters:
other: AUC(0-48): 14052 ± 835 h µg equiv/mL
Toxicokinetic parameters:
other: AUC0-inf: 15124 h µg equiv/mL
Toxicokinetic parameters:
other: kel: 0.0575 ± 0.0069 1/h
Toxicokinetic parameters:
half-life 1st: 12.2 ± 1.4 h

Metabolite characterisation studies

Metabolites identified:
no

Any other information on results incl. tables

Table 3.Tissue Concentrations of Radioactivity and Tissue/Blood Ratios following [35S]MSM Administration to Rats

 

 

concentrationa(µg equiv/g)

 

tissue/blood ratio

tissue

N

48 h

120 h

48 h

120 h

bloodb

3

63.7 ± 12.3

N/A

N/A

N/A

liver

3

54.7 ±11.4

BLQ

0.856

N/A

heart

3

59.4 ±11.7

BLQ

0.932

N/A

kidney

3

71.1 ±15.7

BLQ

1.11

N/A

spleen

3

58.2 ±14.4

BLQ

0.909

N/A

testes

3

69.4 ±16.2

BLQ

1.08

N/A

brain

3

58.7 ±11.8

BLQ

0.921

N/A

eye

3

66.7 ±12.9

BLQ

1.05

N/A

skin

3

51.8 ±13.7

BLQ

0.807

N/A

bone

3

35.2 ±0.9

BLQ

0.563

N/A

aValues are expressed as means ±SD. BLQ, below the limit of quantification; N, number; N/A, not applicable.bThis mean blood concentration uses only the same three animals utilized for tissue analysis.

 

Table 4.Mean Individual and Cumulative Urine, Feces, and Urine +Feces Percent of [35S]MSM Dose Recovered in Ratsa

 

 

 

urine (% of dose)

feces (% of dose)

urine + feces (% of dose)

time (h)

N

individual

cumulative

individual

cumulative

Individual

cumulative

-24 to 0

3

BLQ

BLQ

BLQ

BLQ

BLQ

BLQ

0-24

3

57.1 ±6.2

57.1 ±6.2

1.6 ±0.5

1.6 ±0.5

58.7 ±6.7

58.7 ±6.7

24-48

3

19.2 ±3.9

76.3 ±3.8

1.1 ±0.4

2.7 ±0.4

20.3 ±4.4

79.0 ±4.1

48-72

3

4.3 ±1.3

80.7 ±2.6

0.2 ±0.0

2.9 ±0.3

4.5 ±1.3

83.5 ±2.8

72-96

3

1.2 ±0.3

81.8 ±2.2

0.1 ±0.0

3.0 ±0.3

1.3 ±0.3

84.7 ±2.5

96-120

3

0.3 ±0.1

82.1 ±2.2

0.0 ±0.0

3.0 ±0.3

0.44 ±0.1

85.1 ±2.4

cage wash

2

0.2 ±0.0

82.2 ±2.3

N/A

N/A

0.2 ±0.0

85.2 ±2.5

cage contents

3

3.6 ±3.0

85.8 ±4.8

N/A

N/A

3.6 ±3.0

88.9 ±5.1

total

 

 

85.8 ±4.8

 

3.0 ±0.3

 

88.9 ±5.1

aValues are expressed as means ±SD; BLQ, below the limit of quantification; N, number; N/A, not applicable.

 

Applicant's summary and conclusion

Conclusions:
Interpretation of results (migrated information): no bioaccumulation potential based on study results
MSM is rapidly absorbed, well distributed throughout the body, and quickly eliminated primarily through the urine. No evidence of accumulation in specific tissues was noted.
Executive summary:

The objective of this study was to evaluate the pharmacokinetic profile and distribution of radiolabeled Methylsulfonylmethane (MSM) in rats. Male Sprague-Dawley rats were administered a single oral dose of [35S]MSM (500 mg/kg), and blood levels of radioactivity were determined at different time points for up to 48 h. Tissue levels of radioactivity at 48 and 120 h and urine and fecal radioactivity levels were measured at different time points for up to 120 h following [35S]MSM administration to rats. Oral [35S]MSM was rapidly and efficiently absorbed with a mean tmax of 2.1 h, Cmax of 622 microg equiv/mL, and AUC0-inf of 15124 h.microg equiv/mL. The t1/2 was 12.2 h. Soft tissue distribution of radioactivity indicated a fairly homogeneous distribution throughout the body with relatively lower concentrations in skin and bone. Approximately 85.8% of the dose was recovered in the urine after 120 h, whereas only 3% was found in the feces. No quantifiable levels of radioactivity were found in any tissues after 120 h, indicating complete elimination of [35S]MSM. The results of this study suggest that [35S]MSM is rapidly absorbed, well distributed, and completely excreted from the body.